Cargando…

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Detalles Bibliográficos
Autores principales:	Bain, Stephen C, Carstensen, Bendix, Hyveled, Liselotte, Seremetis, Stephanie, Flindt Kreiner, Frederik, Amadid, Hanan, Clark, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277078/ https://www.ncbi.nlm.nih.gov/pubmed/37328273 http://dx.doi.org/10.1136/bmjdrc-2022-003300

Ejemplares similares

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
por: Friedrichsen, Martin Haljeta, et al.
Publicado: (2023)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment
por: Kreiner, Frederik Flindt, et al.
Publicado: (2012)

HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis
por: Sandnes, Miriam, et al.
Publicado: (2021)

Time trends of cardiovascular risk management in type 1 diabetes - nationwide analyses of real-life data
por: Amadid, Hanan, et al.
Publicado: (2022)

Discrepancy between Serum Ferritin and Liver Iron Concentration in a Patient with Hereditary Hemochromatosis – The Value of T2* MRI
por: Al-Tikrity, Mustafa A., et al.
Publicado: (2020)

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
por: Nørgaard, Caroline Holm, et al.
Publicado: (2022)

Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment
por: Kreiner, Frederik Flindt, et al.
Publicado: (2017)

Surrogate endpoint evaluation using data from one large global randomized controlled trial
por: Geybels, Milan, et al.
Publicado: (2021)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021)

EXPERIMENTAL HEMOCHROMATOSIS
por: Rous, Peyton, et al.
Publicado: (1918)

Hereditary hemochromatosis
por: Geller, Stephen A., et al.
Publicado: (2015)

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
por: Yin, Win L., et al.
Publicado: (2020)

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
por: Zheng, Deqiang, et al.
Publicado: (2023)

Frequency of Hereditary Hemochromatosis Gene (HFE) Variants in Sri Lankan Transfusion-Dependent Beta-Thalassemia Patients and Their Association With the Serum Ferritin Level
por: Padeniya, Padmapani, et al.
Publicado: (2022)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
por: Thompson, Aiysha, et al.
Publicado: (2016)

The Evolution of Iron-Related Comorbidities and Hospitalization in Patients with Hemochromatosis: An Analysis of the Nationwide Inpatient Sample
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Non-HFE hemochromatosis
por: Santos, Paulo Caleb Júnior de Lima, et al.
Publicado: (2012)

Management of cardiac hemochromatosis
por: Aronow, Wilbert S.
Publicado: (2017)

Diabetes in HFE Hemochromatosis
por: Barton, James C., et al.
Publicado: (2017)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

Ferritin Increase in Hemochromatosis Subjects After Discontinuing Their Regular Maintenance Treatment: A Longitudinal Analysis Performed During the COVID-19 Imposed Hospital Lockdown
por: Coutinho, Maria P., et al.
Publicado: (2022)

Molecular basis of HFE-hemochromatosis
por: Vujić, Maja
Publicado: (2014)

Hereditary Hemochromatosis and Iron Metabolism
por: Carlson, Joyce, et al.
Publicado: (2001)

Polycythemia and Anemia in Hereditary Hemochromatosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

What’s Important and New in Hemochromatosis?
por: Brissot, Pierre, et al.
Publicado: (2020)

Fracture Rates in Children with Cerebral Palsy: A Danish, Nationwide Register-Based Study
por: Granild-Jensen, Jakob Bie, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Phlebotomy increases cadmium uptake in hemochromatosis.
por: Akesson, A, et al.
Publicado: (2000)

Molecular Diagnostic and Pathogenesis of Hereditary Hemochromatosis
por: Santos, Paulo C. J. L., et al.
Publicado: (2012)

Neonatal hemochromatosis--report of an autopsy case.
por: Suh, Y. L., et al.
Publicado: (1991)

Hypoparathyroidism and Subclinical Hypothyroidism with Secondary Hemochromatosis
por: Jeong, Hyung Ki, et al.
Publicado: (2014)

Educational Case: Iron Overload and Hemochromatosis
por: Borowitz, Michael J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cm32ineubra8mo23doh424f4br